These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 408431)

  • 21. Immunologic considerations for the development of conjugate vaccines.
    Garner CV; Pier GB
    Contrib Microbiol Immunol; 1989; 10():11-7. PubMed ID: 2510971
    [No Abstract]   [Full Text] [Related]  

  • 22. Meningococcal polysaccharide vaccines: recommendations of the Public Health Service Advisory Committee on Immunization Practices.
    Clin Pediatr (Phila); 1977 Sep; 16(9):764-5. PubMed ID: 408072
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.
    Blanchard-Rohner G; Pollard AJ
    Expert Rev Vaccines; 2011 May; 10(5):673-84. PubMed ID: 21604987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens.
    Kelly DF; Pollard AJ; Moxon ER
    JAMA; 2005 Dec; 294(23):3019-23. PubMed ID: 16414950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of O-acetyl-negative and -positive polysaccharide vaccines for infections with Neisseria meningitidis group C in infants.
    Pichichero M; Anderson P; Gotschlich E; Kamm J; McMullen A; Nielsen S
    J Infect Dis; 1985 Oct; 152(4):850-1. PubMed ID: 3930623
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune response of infants and children to disseminated infections with Neisseria meningitidis.
    Griffiss JM; Brandt BL; Broud DD; Goroff DK; Baker CJ
    J Infect Dis; 1984 Jul; 150(1):71-9. PubMed ID: 6431015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody response to pretreatment immunization and post-treatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin's disease.
    Siber GR; Gorham C; Martin P; Corkery JC; Schiffman G
    Ann Intern Med; 1986 Apr; 104(4):467-75. PubMed ID: 3082268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune responses to polysaccharides: lessons from humans and mice.
    González-Fernández A; Faro J; Fernández C
    Vaccine; 2008 Jan; 26(3):292-300. PubMed ID: 18160186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants.
    Campbell H; Byass P; Ahonkhai VI; Vella PP; Greenwood BM
    Pediatrics; 1990 Jul; 86(1):102-7. PubMed ID: 2113671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunity against Neisseria meningitidis in different population groups].
    Pauste Ruiz H; García Imia L; Campa Huergo C; Gutiérrez Hernández M; Valcárcel Novo M
    Rev Cubana Med Trop; 1989; 41(1):135-47. PubMed ID: 2505344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial retrospective. Meningococcal A and other polysaccharide vaccines. A five-year progress report.
    Lepow ML; Gold R
    N Engl J Med; 1983 May; 308(19):1158-60. PubMed ID: 6403865
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
    Tarkowski A; Lue C; Moldoveanu Z; Kiyono H; McGhee JR; Mestecky J
    J Immunol; 1990 May; 144(10):3770-8. PubMed ID: 2110213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide.
    Peltola H; Käyhty H; Kuronen T; Haque N; Sarna S; Mäkelä PH
    J Pediatr; 1978 May; 92(5):818-22. PubMed ID: 417160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thymic-dependence and immune memory in mice vaccinated with meningococcal polysaccharide group B complexed to outer membrane protein.
    Moreno C; Esdaile J; Lifely MR
    Immunology; 1986 Mar; 57(3):425-30. PubMed ID: 3082745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polysaccharide-specific B cell responses to vaccination in humans.
    Mitchell R; Kelly DF; Pollard AJ; Trück J
    Hum Vaccin Immunother; 2014; 10(6):1661-8. PubMed ID: 24632599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Investigations on the immune response against meningococcal polysaccharide in children (author's transl)].
    Ambrosch F; Stanek G; Jürgenssen O
    Immun Infekt; 1980; 8(1):11-8. PubMed ID: 6773879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further conquest of the meningococcus.
    Lepow ML; Gold R
    N Engl J Med; 1977 Sep; 297(13):721-2. PubMed ID: 408684
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers.
    Glode MP; Lewin EB; Sutton A; Le CT; Gotschlich EC; Robbins JB
    J Infect Dis; 1979 Jan; 139(1):52-9. PubMed ID: 108338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Right age for Meningococcal vaccine.
    John TJ
    Indian Pediatr; 1998 Jul; 35(7):669-70. PubMed ID: 10216680
    [No Abstract]   [Full Text] [Related]  

  • 40. Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Wong VK; Quagliata R; Adler R; Kim KS
    Am J Dis Child; 1991 Jul; 145(7):742-5. PubMed ID: 2058604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.